{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:26:38Z","timestamp":1780104398345,"version":"3.54.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40801-022-00325-3","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T09:03:11Z","timestamp":1660381391000},"page":"649-657","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of Tolvaptan in Patients with Chronic Kidney Disease Stage G5, and Impact of Concomitant Use of Thiazide Diuretics: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5173-1263","authenticated-orcid":false,"given":"Kiyotaka","family":"Uchiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko Yoshida","family":"Hama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashin","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohkichi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Washida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,13]]},"reference":[{"key":"325_CR1","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","volume":"83","author":"H Tsutsui","year":"2019","unstructured":"Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group, et al. JCS 2017\/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure - Digest Version. Circ J. 2019;83:2084\u2013184.","journal-title":"Circ J"},{"key":"325_CR2","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319\u201331.","journal-title":"JAMA"},{"key":"325_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1253\/circj.CJ-17-0179","volume":"82","author":"T Inomata","year":"2017","unstructured":"Inomata T, Ikeda Y, Kida K, Shibagaki Y, Sato N, Kumagai Y, Kanagawa Aquaresis Investigators, et al. Effects of additive tolvaptan vs increased furosemide on heart failure with diuretic resistance and renal impairment: results from the K-STAR study. Circ J. 2017;82:159\u201367.","journal-title":"Circ J"},{"key":"325_CR4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1007\/s10157-013-0788-6","volume":"17","author":"T Otsuka","year":"2013","unstructured":"Otsuka T, Sakai Y, Ohno D, Murasawa T, Sato N, Tsuruoka S. The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. Clin Exp Nephrol. 2013;17:834\u20138.","journal-title":"Clin Exp Nephrol"},{"key":"325_CR5","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s10157-016-1379-0","volume":"21","author":"M Katsumata","year":"2017","unstructured":"Katsumata M, Hirawa N, Sumida K, Kagimoto M, Ehara Y, Okuyama Y, et al. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure. Clin Exp Nephrol. 2017;21:858\u201365.","journal-title":"Clin Exp Nephrol"},{"key":"325_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000381859","volume":"130","author":"H Iwatani","year":"2015","unstructured":"Iwatani H, Kawabata H, Sakaguchi Y, Yamamoto R, Hamano T, Rakugi H, et al. Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study. Nephron. 2015;130:8\u201312.","journal-title":"Nephron"},{"key":"325_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJM196004142621501","volume":"262","author":"JD Crawford","year":"1960","unstructured":"Crawford JD, Kennedy GC, Hill LE. Clinical results of treatment of diabetes insipidus with drugs of the chlorothiazide series. N Engl J Med. 1960;262:737\u201343.","journal-title":"N Engl J Med"},{"key":"325_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12882-018-0957-7","volume":"19","author":"BJ Kramers","year":"2018","unstructured":"Kramers BJ, van Gastel MDA, Meijer E, Gansevoort RT. Case report: a thiazide diuretic to treat polyuria induced by tolvaptan. BMC Nephrol. 2018;19:157.","journal-title":"BMC Nephrol"},{"key":"325_CR9","doi-asserted-by":"publisher","first-page":"17666","DOI":"10.1038\/s41598-021-97113-w","volume":"11","author":"K Uchiyama","year":"2021","unstructured":"Uchiyama K, Kitayama C, Yanai A, Ishibashi Y. The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial. Sci Rep. 2021;11:17666.","journal-title":"Sci Rep"},{"key":"325_CR10","first-page":"291","volume":"22","author":"F Kuzuya","year":"1984","unstructured":"Kuzuya F, Sugino N, Yoshizumi K, Goto U, Oshima K. Clinical investigations on the pharmacology of azosemide (SK-110) in comparison with furosemide in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1984;22:291\u20139.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"325_CR11","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"325_CR12","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1001\/jama.2010.748","volume":"303","author":"H Bueno","year":"2010","unstructured":"Bueno H, Ross JS, Wang Y, Chen J, Vid\u00e1n MT, Normand SL, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993\u20132006. JAMA. 2010;303:2141\u20137.","journal-title":"JAMA"},{"key":"325_CR13","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/00041552-199309000-00014","volume":"2","author":"WT Abraham","year":"1993","unstructured":"Abraham WT, Schrier RW. Edematous disorders: pathophysiology of renal sodium and water retention and treatment with diuretics. Curr Opin Nephrol Hypertens. 1993;2:798\u2013805.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"325_CR14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/ki.1987.192","volume":"32","author":"M Inoue","year":"1987","unstructured":"Inoue M, Okajima K, Itoh K, Ando Y, Watanabe N, Yasaka T, et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int. 1987;32:198\u2013203.","journal-title":"Kidney Int"},{"key":"325_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.semnephrol.2011.09.003","volume":"31","author":"DC Brater","year":"2011","unstructured":"Brater DC. Update in diuretic therapy: clinical pharmacology. Semin Nephrol. 2011;31:483\u201394.","journal-title":"Semin Nephrol"},{"key":"325_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000047397","volume":"96","author":"DH Ellison","year":"2001","unstructured":"Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96:132\u201343.","journal-title":"Cardiology"},{"key":"325_CR17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/sdi.12130","volume":"26","author":"E Streja","year":"2013","unstructured":"Streja E, Nicholas SB, Norris KC. Controversies in timing of dialysis initiation and the role of race and demographics. Semin Dial. 2013;26:658\u201366.","journal-title":"Semin Dial"},{"key":"325_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"325_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/00041552-200309000-00001","volume":"12","author":"DA Sica","year":"2003","unstructured":"Sica DA, Gehr TW. Diuretic use in stage 5 chronic kidney disease and end-stage renal disease. Curr Opin Nephrol Hypertens. 2003;12:483\u201390.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"325_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1600-0773.1984.tb03626.x","volume":"54","author":"B Beermann","year":"1984","unstructured":"Beermann B. Aspects on pharmacokinetics of some diuretics. Acta Pharmacol Toxicol (Copenh). 1984;54:17\u201329.","journal-title":"Acta Pharmacol Toxicol (Copenh)."},{"key":"325_CR21","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/0002-9343(82)90854-3","volume":"72","author":"GL Wollam","year":"1982","unstructured":"Wollam GL, Tarazi RC, Bravo EL, Dustan HP. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med. 1982;72:929\u201338.","journal-title":"Am J Med"},{"key":"325_CR22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/ki.1994.298","volume":"46","author":"D Fliser","year":"1994","unstructured":"Fliser D, Schr\u00f6ter M, Neubeck M, Ritz E. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int. 1994;46:482\u20138.","journal-title":"Kidney Int"},{"key":"325_CR23","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1681\/ASN.V1271335","volume":"12","author":"JG Abdallah","year":"2001","unstructured":"Abdallah JG, Schrier RW, Edelstein C, Jennings SD, Wyse B, Ellison DH. Loop diuretic infusion increases thiazide-sensitive Na(+)\/Cl(-)-cotransporter abundance: role of aldosterone. J Am Soc Nephrol. 2001;12:1335\u201341.","journal-title":"J Am Soc Nephrol"},{"key":"325_CR24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/HCO.0000000000000188","volume":"30","author":"AD Sinha","year":"2015","unstructured":"Sinha AD, Agarwal R. Thiazides in advanced chronic kidney disease: time for a randomized controlled trial. Curr Opin Cardiol. 2015;30:366\u201372.","journal-title":"Curr Opin Cardiol"},{"key":"325_CR25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1681\/ASN.2019090905","volume":"31","author":"DM Bov\u00e9e","year":"2020","unstructured":"Bov\u00e9e DM, Visser WJ, Middel I, De Mik-van EA, Greupink R, Masereeuw R, et al. A randomized trial of distal diuretics versus dietary sodium restriction for hypertension in chronic kidney disease. J Am Soc Nephrol. 2020;31:650\u201362.","journal-title":"J Am Soc Nephrol"},{"key":"325_CR26","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","volume":"385","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, Tu W. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021;385:2507\u201319.","journal-title":"N Engl J Med"},{"key":"325_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1159\/000481995","volume":"46","author":"N Tominaga","year":"2017","unstructured":"Tominaga N, Kida K, Inomata T, Sato N, Izumi T, Akashi YJ, et al. Effects of tolvaptan addition to furosemide in normo- and hyponatremia patients with heart failure and chronic kidney disease stages G3b\u20135: a subanalysis of the K-STAR study. Am J Nephrol. 2017;46:417\u201326.","journal-title":"Am J Nephrol"},{"key":"325_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/phar.2239","volume":"39","author":"EG Gunderson","year":"2019","unstructured":"Gunderson EG, Lillyblad MP, Fine M, Vardeny O, Berei TJ. Tolvaptan for volume management in heart failure. Pharmacotherapy. 2019;39:473\u201385.","journal-title":"Pharmacotherapy"},{"key":"325_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s10157-013-0883-8","volume":"18","author":"T Iwahori","year":"2014","unstructured":"Iwahori T, Esaki M, Hinoue H, Esaki S, Esaki Y. Tolvaptan increases urine and ultrafiltration volume for patients with oliguria undergoing peritoneal dialysis. Clin Exp Nephrol. 2014;18:655\u201361.","journal-title":"Clin Exp Nephrol"},{"key":"325_CR30","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3747\/pdi.2013.00290","volume":"35","author":"T Hiramatsu","year":"2015","unstructured":"Hiramatsu T, Hobo A, Hayasaki T, Kabu K, Furuta S. A pilot study examining the effects of tolvaptan on residual renal function in peritoneal dialysis for diabetics. Perit Dial Int. 2015;35:552\u20138.","journal-title":"Perit Dial Int"},{"key":"325_CR31","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/ndt\/gfaa148","volume":"36","author":"H Ogata","year":"2021","unstructured":"Ogata H, Shimofurutani N, Okada T, Nagamoto H, Akizawa T. Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a Phase 2, double-blind, randomized, placebo-controlled trial. Nephrol Dial Transplant. 2021;36:1088\u201397.","journal-title":"Nephrol Dial Transplant"},{"key":"325_CR32","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, TEMPO 3:4 Trial Investigators, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407\u201318.","journal-title":"N Engl J Med"},{"key":"325_CR33","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, REPRISE Trial Investigators, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930\u201342.","journal-title":"N Engl J Med"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00325-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-022-00325-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00325-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T19:33:50Z","timestamp":1669836830000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-022-00325-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["325"],"URL":"https:\/\/doi.org\/10.1007\/s40801-022-00325-3","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,13]]},"assertion":[{"value":"26 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Original data are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Kiyotaka Uchiyama, Daiki Kojima, Eriko Yoshida Hama, Tomoki Nagasaka, Takashin Nakayama, Rina Takahashi, Takaya Tajima, Kohkichi Morimoto, Naoki Washida, and Hiroshi Itoh declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was reviewed and approved by the Research Ethics Committee of Keio University, School of Medicine (approval number: 20211114) and was performed in accordance with the principles of the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Due to the retrospective design of this study, informed consent for study participation was obtained in the form of an opt-out method on the website.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Due to the retrospective design of this study, informed consent for publication of study findings was obtained in the form of an opt-out method on the website.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"KU designed the study and wrote the initial draft of the manuscript. KU, DK, EYH, TNag, TNak, RT, and TT contributed to data collection. KU, TNak, and KM contributed to the analysis and interpretation of data. NW and HI supervised the manuscript. All authors have approved the final version of the manuscript and agree to be accountable for all aspects of the work as well as ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}